(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit.

IHH Healthcare is seeking compensation of up to $1.7b (₹109.3b) from Japanese drugmaker Daiichi Sankyo for its stake buy in India’s Fortis Healthcare.

Delhi: IHH Healthcare, a prominent global healthcare provider, has escalated its legal battle with Japan's Daiichi Sankyo, ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao ...

IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...

Malaysia's IHH Healthcare said on Thursday its unit is seeking compensation of up to 109.3 billion rupees ($1.25 billion) ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective ...

Northern TK Venture Pte Ltd, IHH Healthcare's Singaporean arm, has raised its claim against Daiichi Sankyo in Tokyo for ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive ...